

CLAIMS

1. Use of an anti-IFNAR antibody in the manufacture of a medicament for treating SLE in a subject, wherein a therapeutically effective amount of the anti-IFNAR antibody is to be administered to the subject, wherein the patient has an elevated interferon protein signature (IFNPS) characterised by elevated protein expression of EPHB2, BLC, LAG-3 and IP-10 in the serum compared to a subject not having SLE, wherein the anti-IFNAR antibody is anifrolumab or a functional derivative thereof.
2. The use of claim 1, comprising administration of 300 mg anifrolumab, optionally wherein the method comprises intravenous administration of 300 mg anifrolumab every 4 weeks.
3. The use of any preceding claim, wherein the treatment suppresses the IFNPS.
4. The use of claim 1, wherein the treatment results in an improvement of the subject's SLE Disease Activity Index (SLEDAI).
5. The use of claim 1, wherein the treatment results in an improvement of the subject's Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) activity score.
6. The use of any preceding claim, wherein the subject is identified as not having an elevated IFNPS signature compared to a subject not having SLE.
7. The use of any preceding claim, wherein the treatment decreases the elevated IFNPS signature.
8. An *in vitro* method for detecting elevated IFN activity in a sample isolated from a subject, the *in vitro* method comprising quantifying EPHB2, BLC, LAG-3 and IP-10 protein expression in the sample and comparing the protein expression in the sample with EPHB2, BLC, LAG-3 and IP-10 protein expression in a sample from a healthy donor.